La catena delle opzioni mostra i dati chiave delle opzioni azionarie di CASI Pharmaceuticals a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per CASI Pharmaceuticals..

CASI Pharmaceuticals (NASDAQ:CASI) Azioni, Catena delle Opzioni

CASI Pharmaceuticals

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Inc

CASINO GHRD PRC S/ADR by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA

CASINO GUICHARD PERRACHON by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA ADR

CASIO COMPUTER CO LTD by Casio Computer Co., Ltd.

Casio Computer Co Ltd

CASIO COMPUTER UNSP/ADR by Casio Computer Co., Ltd.

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>CASI Pharmaceuticals</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/casi-stock-quote/"><strong>CASI</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>CASI Pharmaceuticals reported earnings per share of -52 cents. This was above the analyst estimate for EPS of -63 cents.</li><li>The company reported revenue of $3.98 million.</li><li>This was 10.18% worse than the analyst estimate for revenue of $4.43 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/casi-stock-earnings-casi-pharmaceuticals-for-q2-of-2024/">CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024

Casi Pharmaceuticals files to sell 3M ordinary shares for holders.

Novartis expands U.S. radiopharma production amid rising competition

CASI Pharmaceuticals (CASI) has released an update. CASI Pharmaceuticals has restructured its senior management to better align with its strategic ...

CASI Pharmaceuticals Revamps Management Structure

CASI Pharmaceuticals (CASI) announced that the Center for Drug Evaluation of China's National Medical Products Administration has approved the Comp...

Casi Pharmaceuticals receives CTA approval from China NMPA for CID-103

CASI Pharmaceuticals Q3 Earnings Preview

Here's the major earnings before the open tomorrow

CASI Pharmaceuticals reports Q3 results

CASI Pharmaceuticals (CASI) has released an update. CASI Pharmaceuticals reported a 12% decrease in third-quarter revenue in 2024 compared to the p...

CASI Pharmaceuticals' Mixed Third-Quarter Performance in 2024

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.&nbsp; 1. STOCK NEWS: Shares of Domino's Pizza (DPZ) w...

Berkshire reveals stake in Domino's, Alibaba reports mixed Q2: Morning Buzz

AFMD

ALHC

AMAT

AMZN

ASTS

ATNM

AZUL

BABA

BILI

BLUE

BTAI

CASI

CATX

CLRB

CRIS

CVSI

DESP

DTEGY

EONGY

HALO

ITRM

KEYUF

KNTNF

LNTH

LUNR

MKGAF

NICE

NLCP

NTES

NVSEF

OCUL

ONEW

PAVM

PDSB

POLA

PVCT

QBTS

RCAT

SACH

SEDG

SIEGY

SLGL

SPCB

SSNLF

TRUG

TWLO

VEON

VISL

WKHS

XNET

Press Releases

CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)

CASI Pharmaceuticals Announces $15 Million Private Placement Financing by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture and Dr. Wei-Wu He

CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP

Small Cap

CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS

Ligand Reports Second Quarter 2024 Financial Results

Earnings

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

News

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

Comments

CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) Opzioni

CASI Pharmaceuticals (NASDAQ:CASI) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO